CHClaudia Herrera-Deguise

Claudia Herrera-Deguise

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claudia Herrera-Deguise has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fecal calprotectin changes after polyethylene glycol bowel preparation in patients with ulcerative colitis in remission

    by Claudia Herrera-Deguise, Encarna Varela, Virginia Robles Alonso, Luis Mayorga Ayala, Elena Céspedes Martinez, Xavier Serra Ruiz, Ernesto Lastiri, Elena Oller, Zahira Perez, Natalia Borruel Sainz

    This prospective paired-sample study evaluated fecal calprotectin changes after polyethylene glycol-based bowel preparation in ulcerative colitis patients in remission. Calprotectin increased modestly, particularly in patients with Mayo 1 endoscopic subscore, but clinical worsening was uncommon and healthy individuals showed no significant change.

  • Open Access

    Fungal abundance across flare and remission in ulcerative colitis patients

    by Claudia Herrera-Deguise, Encarna Varela, Guillaume Sarrabayrouse, Francisca Yáñez, Luis Mayorga-Ayala, Virginia Robles-Alonso, Elena Céspedes-Martínez, Xavier Serra-Ruiz, Ernesto Lastiri, Francisco Guarner, et al.

    Ulcerative colitis (UC) is associated with gut microbiota alterations, but the role of the fungal microbiota remains underexplored. We conducted a prospect

  • Top Cited Papers
    Open Access

    Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis

    by Luis Mayorga, Arnau Noguera Segura, Laura Campderros, Marc Pons-Tarin, Zaida Soler, Sara Vega-Abellaneda, Gerard Serrano-Gomez, Claudia Herrera-Deguise, Virginia Robles-Alonso, Natalia Borruel, et al.

    Background: Inflammatory bowel disease (IBD) arises from complex interactions among diet, host and gut microbiome. Although diet influences intestinal inflammation, the microbial and metabolic pathways involved, and their differences between Crohn’s disease (CD) and ulcerative colitis (UC), the two main subtypes of IBD remain unclear. Objective: To investigate how the gut microbiome mediates the effects of habitual diet on inflammatory activity in IBD. Design: This longitudinal study included 198 adults (100 healthy controls, 49 CD, 49 UC), participants completed a validated food frequency questionnaire. Dietary quality was evaluated using established indices (Alternative Mediterranean Diet, Healthy Eating Index-2015, Índice de Alimentación Saludable, Mean Adequacy Ratio, Plant-Based Dietary Indexes, Healthy Food Diversity). Participants also provided two stool samples (baseline and 6 months). Shotgun metagenomics (n=366) enabled taxonomic and functional profiling. Causal mediation analyses were used to identify microbial features mediating the effect of diet on inflammation. Results: IBD patients exhibited lower dietary diversity, fibre intake and nutritional adequacy compared with controls. Microbiome diversity was lowest in CD, intermediate in UC and correlated positively with higher intake of fibre, fruit, vegetables and nuts, and negative with processed foods and sugary beverages. Causal mediation analyses revealed that in CD, coffee, whole wheat bread and healthier diets lowered the Harvey-Bradshaw index through specific bacterial species and metabolites. In UC, Mediterranean-like diets, fruits and coffee reduced C reactive protein via greater microbial richness, reduced dysbiosis and short-chain fatty acid-related functions. Conclusion: Diet quality influences inflammation in IBD through distinct microbiome pathways: specific taxa and metabolites mediate effects in CD, whereas microbial richness and global composition drive protection in UC.


  • Open Access

    Higher ustekinumab concentrations in induction are associated with better endoscopic outcomes in inflammatory bowel disease

    by Xavier Serra-Ruiz, Elena Céspedes-Martínez, Luis Mayorga, Claudia Herrera-Deguise, Virginia Robles, Ernesto Lastiri, Sonia Garcia-Garcia, María Larrosa-García, María Teresa Sanz-Martínez, Zahira Pérez, et al.

    Background: Evidence suggests a relationship between ustekinumab (UST) concentrations and therapeutic outcomes in inflammatory bowel disease. Objectives: This study aimed to evaluate the association between UST concentrations during the induction phase and treatment outcomes at week 24 in patients with Crohn’s disease (CD) and ulcerative colitis (UC). The primary outcome was endoscopic remission at week 24, defined as a simple endoscopic score (SES-CD) ⩽2 for CD and a Mayo endoscopic score = 0 for UC. Secondary outcomes included endoscopic response, clinical remission, and treatment persistence. Design: This was a prospective observational study assessing clinical and endoscopic outcomes in CD and UC patients starting UST therapy. Methods: Consecutive patients with CD and UC were included at the initiation of UST treatment. Trough UST concentrations were measured at weeks 8, 16, and 24 after the first intravenous dose, and the main outcomes were assessed at week 24. Endoscopic and clinical parameters were used to evaluate treatment efficacy and persistence. Results: Seventy patients (45 with CD) were enrolled. Those achieving endoscopic remission and response at week 24 had higher UST levels at week 8 (4.5 vs 2.6 μg/mL, p = 0.0028; 4.1 vs 2.4 μg/mL, p = 0.0024, respectively). Patients with UST concentrations in the fourth quartile (Q4) at week 8 (>4.5 μg/mL) had higher rates of endoscopic remission (66.7% (Q4) vs 20% (Q1); 33.3% (Q2); 28.6% (Q3); p = 0.012). A UST concentration threshold of 4.5 μg/mL at week 8 was the best predictor of endoscopic remission (AUC = 0.7, sensitivity 54.5%, specificity 83.8%), while 3.5 μg/mL predicted endoscopic response (AUC = 0.732, sensitivity 53.8%, specificity 87%). Longer disease duration correlated with a higher risk of UST discontinuation (odds ratio, 1.034, 95% confidence interval, 1.002–1.068, p = 0.035). Higher UST concentrations in Q4 did not result in greater drug persistence ( p = 0.319). Conclusion: UST concentrations at week 8 were positively associated with endoscopic outcomes at week 24, with a threshold of 4.5 μg/mL reliably predicting endoscopic remission. Further randomized clinical trials are warranted to explore whether optimizing UST treatment based on post-induction concentrations can enhance therapeutic outcomes.

  • Open Access

    Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients

    by Luis Mayorga Ayala, Claudia Herrera-Deguise, Juliana Esperalba, Xavier Martinez-Gomez, Elena Céspedes Martinez, Xavier Serra Ruiz, Virginia Robles, Ernesto Lastiri, Zahira Perez, Elena Oller, et al.

    Background: Studies investigating the long-term cellular immune response to SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease (IBD) remain limited, particularly among those receiving immunosuppressive therapy. Methods: We prospectively evaluated humoral and cellular immune responses at short-term (4–6 weeks) and long-term (6–12 months) time points following SARS-CoV-2 mRNA vaccination in patients with IBD receiving anti-TNF agents, thiopurines, or combination therapy. We defined the short-term response as the measurement taken 4–6 weeks after the second vaccine dose and the long-term response as the measurement taken between 6 and 12 months after the first determination. A cohort of healthy controls was included for short-term comparative analysis. Results: At long-term follow-up, quantitative humoral responses were reduced in patients receiving anti-TNF monotherapy. In contrast, a reduced quantitative cellular response was found in the thiopurine (median 0.7 UI/mL, p < 0.05) and anti-TNF combo groups (median 0.4 UI/mL, p < 0.01) compared to anti-TNF monotherapy (median 2.2 UI/mL). Conclusions: There was a robust long-term humoral and cellular response to vaccination, but a diminished quantitative cellular response in patients treated with thiopurines or combo therapy compared to anti-TNF monotherapy.


  • Bile acid malabsorption diarrhea as a clinical manifestation of terminal ileum endometriosis

    by Claudia Herrera-Deguise, Marina Planes-Conangla, Miquel Kraft Carré, Miquel Masachs

  • Open Access

    Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study

    by Iago Rodríguez-Lago, Claudia Herrera-Deguise, Maia Boscá-Watts, Cristina Rodríguez, Eduardo Leo-Carnerero, María Calvo Íñiguez, Fiorella Cañete, Silvia Chacón, Camila Cuarán, Ainara Elorza, et al.

  • Open Access

    Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study

    by Iago Rodríguez-Lago, Fiorella Cañete, Elena Guerra-Del-Río, Claudia Herrera-Deguise, Eva Iglesias, Eduardo Leo, Yamile Zabana, Manuel Barreiro-De Acosta, Daniel Ginard, José Luis Cabriada


  • Gut Microbiota Composition in Long-Remission Ulcerative Colitis is Close to a Healthy Gut Microbiota

    by Claudia Herrera-Deguise, Encarna Varela, Guillaume Sarrabayrouse, Marta Pozuelo del Río, Virginia Robles Alonso, Natalia Borruel Sainz, Francesc Casellas, Luis Fernando Mayorga, Chaysavanh Manichanh, Fernando Azpiroz Vidaur, et al.

    Background: Microbiome studies report low gut microbial richness and diversity in ulcerative colitis (UC) patients. We explored whether UC patients who reach long-term clinical, endoscopic, and histological remission show a gut microbial ecosystem that is similar to healthy individuals. Methods: We collected 184 stool samples from 111 individuals (UC patients in long remission, short remission, flare, and healthy control subjects). Microbiota was analyzed by amplicon sequencing (16S ribosomal RNA) and quantitative polymerase chain reaction for specific taxa. All UC remission patients were followed-up for 2 years. Findings: A drop in species diversity and richness, underrepresentation of butyrate producers, and gain of potentially harmful bacteria were significantly detected in samples from disease-flare and short-remission patients. In contrast, Chao1 and Shannon indexes of diversity did not differ among patients in long remission and healthy control subjects. Long-remission patients also presented fecal bacterial composition closer to that in healthy control subjects. There was a positive correlation between Akkermansia muciniphila abundance and time in remission (rs = 0.53, P < .001). Logistic regression analysis showed that a high Shannon index (odds ratio, 4.83; 95% confidence interval, 1.5-20.6) or presence of A. muciniphila (odds ratio, 4.9; 95% confidence interval, 1.12-29.08) in fecal samples at entry was independently associated with clinical remission over a follow-up period of 24 months. Interpretation: UC patients who achieve long-term remission show evidence of substantial recovery of the gut microbial ecosystem in terms of diversity and composition. Recovery may just reflect adequate control of inflammatory activity, but higher bacterial diversity or the presence of A. muciniphila in fecal samples predicts flare-free outcomes.


  • Open Access

    Effectiveness of a Telephone-Based Motivational Intervention for Smoking Cessation in Patients With Crohn Disease

    by Ester Msn Navarro Correal, Francesc Casellas Jorda, Natalia Borruel Sainz, Virginia Robles Alonso, Claudia Herrera de Guise, Arantxa Msn Ibarz Casas, Josep Maria Sánchez García, Genoveva Vila Morte, Carmen Rn Fuentelsaz Gallego

    A randomized, open-label, controlled clinical trial was designed to assess the effectiveness of a motivational intervention based on the 5 R's model (relevance, risks, rewards, roadblocks, and repetition) delivered by specialized inflammatory bowel disease nurses every 3 months over a 1-year period as compared with patients who were followed regularly. Patients diagnosed with Crohn disease, aged 18 years or older, who reported being active smokers with Internet access at home and an e-mail address were eligible. A total of 144 patients (72 per group) were included (50% women, median age 40 years). They smoked a median of 10 cigarettes per day (range = 1–40) and had been smoking for a median of 22 years (range = 1–51). Motivation to quit (Richmond test) was low in 73 patients, moderate in 39 patients, and high in 32 patients. Statistically significant differences between the study groups in the predisposition to change, motivation to quit, and tobacco withdrawal were not found. However, 14 patients (20.9%) in the intervention group and 9 patients (13.2%) among controls stopped smoking at the end of the study. These findings support a higher trend toward smoking cessation associated with the motivational intervention 5 R's. This behavioral strategy can aid patients with Crohn disease to quit smoking.